Volume 5.06 | Feb 18

Pulmonary Cell News 5.06 February 18, 2016
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PULCN on Twitter
Researchers Find a Potential Therapy for the Most Aggressive Type of Lung Cancer in Preclinical Models
The specific combination of the drugs dasatinib and demcizumab impairs the growth of KRAS-driven lung tumors, the most aggressive sub-type and with the lowest survival rates. This combination of drugs could represent a new therapy directed against these tumors, which are currently treated with the standard cisplatin-based therapy. [Press release from Spanish National Cancer Research Centre discussing online publication in Nature Medicine] Press Release | Abstract
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)
Thrombin Stimulates Albumin Transcytosis in Lung Microvascular Endothelial Cells via Activation of Acid Sphingomyelinase
Researchers tested the hypothesis that thrombin may stimulate transcellular albumin transport across lung microvascular endothelial cells in an acid-sphingomyelinase dependent manner. [Am J Physiol Lung Cell Mol Physiol] Abstract

Increased Susceptibility of cftr-/- Mice to LPS-Induced Lung Remodeling
Investigators characterized the lung pathology and the immune response of cftr-/- and cftr+/+ mice to chronic administration of Pseudomonas aeruginosa lipopolysaccharide. [Am J Physiol Lung Cell Mol Physiol] Abstract

Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease
Researchers aimed to determine whether inducible, mesenchyme-specific VEGF inhibition in the neonatal mouse lung results in long-term modulation of alveolar epithelial type II cells and whole lung function. [PLoS One] Full Article

Protective Effects of Myrtol Standardized against Radiation-Induced Lung Injury
Investigators evaluated the effects of Myrtol standardized on radiation-induced lung injury, and to investigate the underlying mechanism. A mouse model of radiation-induced lung injury was generated by using thoracic irradiation with a single dose of 16 Gy. [Cell Physiol Biochem] Full Article

Human Bronchial Epithelial Cells Exposed In Vitro to Diesel Exhaust Particles Exhibit Alterations in Cell Rheology and Cytotoxicity Associated with Decrease in Antioxidant Defenses and Imbalance in Pro- and Anti-Apoptotic Gene Expression
Scientists used human bronchial epithelium cells in culture and evaluated their exposure to diesel exhaust particles in order to determine changes to cell rheology (viscoelasticity) and gene expression of the enzymes involved in oxidative stress, apoptosis, and cytotoxicity. [Environ Sci Pollut Res Int] Abstract


Histone Acetyltransferase Inhibitor CPTH6 Preferentially Targets Lung Cancer Stem-Like Cells
Investigators evaluated the efficacy of the thiazole derivative 3-methylcyclopentylidene-[4-(4′-chlorophenyl)thiazol-2-yl]hydrazone (CPTH6), a novel pCAF and Gcn5 histone acetyltransferase inhibitor, as a small molecule that preferentially targets lung cancer stem-like cells derived from non-small cell lung cancer patients. [Oncotarget] Full Article

Lovastatin Lactone Elicits Human Lung Cancer Cell Apoptosis via a COX-2/PPAR╬│-dependent Pathway
In A549 and H358 lung carcinoma cells the lipophilic prodrug lovastatin lactone led to a concentration-dependent decrease of viability and induction of DNA fragmentation, whereas its 3-hydroxy-3-methylglutaryl coenzyme A-inhibitory, ring-open acid form was inactive in this respect. [Oncotarget] Abstract

Colchicine Induces Autophagy and Senescence in Lung Cancer Cells at Clinically Admissible Concentration: Potential Use of Colchicine in Combination with Autophagy Inhibitor in Cancer Therapy
Researchers investigated the possible mechanism by which the efficacy of colchicine against lung cancer cells at a less toxic dose could be enhanced. Colchicine at clinically admissible concentration of 2.5 nM had no cytotoxic effect and caused no G2/M arrest in A549 cells. [Tumor Biol] Abstract

Marine Steroid Derived from Acropora formosa Enhances Mitochondrial-Mediated Apoptosis in Non-Small Cell Lung Cancer Cells
The authors isolated 2-ethoxycarbonyl-2-╬▓-hydroxy-A-nor-cholest-5-ene-4one (ECHC) from butanol extracts of scleractinian coral (Acropora formosa) and reported its potential antioxidant and antimicrobial activity as well as less toxicity against zebrafish (Danio rerio). They explored p53-mediated apoptosis pathway enhanced by ECHC in A549 human non-small cell lung cancer cell lines. [Tumor Biol] Abstract

Activation of MEK1/2-ERK1/2 Signaling during NNK-Induced Lung Carcinogenesis in Female a/J Mice
To study the association of extracellular signal-regulated kinase 1/2 (ERK1/2) activation with mutation of Kras encoding an upstream activator of ERK1/2 in lung premalignant lesions, scientists immunohistochemically examined expression of phosphorylated forms of ERK1/2 and MAP/ERK kinase 1/2 proteins and correlation between ERK activation and mutation of Kras encoding an upstream activator of ERK1/2, in a mouse lung carcinogenesis model. [Cancer Med] Full Article

Video Protocol: Mucociliary Differentiation of Primary Bronchial Epithelial Cells
Primary Cilia: Control Centers for Stem Cell Lineage Specification and Potential Targets for Cell-Based Therapies
The authors highlight the cilium’s function and integrate this knowledge into the working knowledge of stem cell biologists and tissue engineers developing regenerative medicine technologies. [Stem Cells] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Clovis Oncology Announces Rociletinib New Drug Application Scheduled for Presentation at Upcoming FDA Oncologic Drugs Advisory Committee Meeting
Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application for rociletinib for discussion by the Oncologic Drugs Advisory Committee. Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. [Clovis Oncology, Inc.] Press Release

HOPE Donates $100,000 to American Cancer Society for Genetic Research in Lung Cancer
HOPE (Health Opportunity through Partnership in Education), together with Washington National Insurance Company, has donated $100,000 to help the American Cancer Society fund cutting-edge scientific cancer research. The $100,000 gift will help fund a post-doctoral fellowship genetic research project in lung cancer at the Dana-Farber Cancer Institute in Boston. [Washington National Insurance Company (PR Newswire Association LLC)] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 12th International Conference of the Asian Clinical Oncology Society
April 8-10, 2016
New Delhi, India

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Associate or Full Professor – Cardiothoracic Surgery (University of California San Diego)

Scientist – Lung Stem Cells (United Therapeutics Corporation)

Postdoctoral Research Fellow – Lung Cancer (Cornell University)

PhD Student Position – Asthma Research (Karolinska Institutet)

Postdoctoral Fellow – Lung Cancer Research (German Cancer Research Center)

Project Scientist – Pulmonary Fibrosis (Cedars Sinai Medical Center)

Postdoctoral Fellow – Bioinformatics RNA Biology & Cancer (German Cancer Research Center)

Postdoctoral Fellow/Research Associate – Cancer Therapy (Memorial Sloan Kettering Cancer Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Immunology (Research Centre for Respiratory Diseases)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us